DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders — Sep 25th, 2024

Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient. Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders MIAMI, Sept. 25, 2024 /PRNewswire/ -- DOMA Perpetual Capi...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee — Sep 26th, 2024

Pacira BioSciences -- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentati...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee — Sep 26th, 2024

Pacira BioSciences -- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentati...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders — Sep 25th, 2024

Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient. Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders MIAMI, Sept. 25, 2024 /PRNewswire/ -- DOMA Perpetual Capi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) — Oct 7th, 2024

Pacira BioSciences TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira’...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer — Oct 21st, 2024

Pacira BioSciences Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioi...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee — Sep 26th, 2024

Pacira BioSciences -- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentati...

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings — Oct 5th, 2024

Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders should be happy to see the share price up 14% in the last week. But that doesn't change the fact that the returns over the last three years have been disappointing. Indeed, the share price is down a tragic 66% in the last three years. So ...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 — Oct 3rd, 2024

Pacira BioSciences -- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inn...